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Abstract
Suppressors of cytokine signaling 1 and 3 (SOCS-1 and SOCS-3) are inhibitors of the Janus tyrosine kinase (JAK)/
signal transducers and activators of transcription (STAT) pathway and function in a negative feedback loop during
cytokine signaling. Abl transformation is associated with constitutive activation of JAK/STAT–dependent signaling.
However, the mechanism by which Abl oncoproteins bypass SOCS inhibitory regulation remains poorly defined.
Here, we demonstrate that coexpression of Bcr-Abl with SOCS-1 or SOCS-3 results in tyrosine phosphorylation of
these SOCS proteins. Interestingly, SOCS-1 is highly tyrosine phosphorylated in one of five primary chronic mye-
logenous leukemia samples. Bcr-Abl–dependent tyrosine phosphorylation of SOCS-1 and SOCS-3 occurs mainly
on Tyr 155 and Tyr 204 residues of SOCS-1 and on Tyr 221 residue of SOCS-3. We observed that phosphorylation
of these SOCS proteins was associated with their binding to Bcr-Abl. Bcr-Abl–dependent phosphorylation of SOCS-1
and SOCS-3 diminished their inhibitory effects on the activation of JAK and STAT5 and thereby enhanced JAK/STAT5
signaling. Strikingly, disrupting the tyrosine phosphorylation of SOCS-1 or SOCS-3 impaired the expression of Bcl-XL
protein and sensitized K562 leukemic cells to undergo apoptosis. Moreover, selective mutation of tyrosine phos-
phorylation sites of SOCS-1 or SOCS-3 significantly blocked Bcr-Abl–mediated tumorigenesis in nude mice and inhib-
ited Bcr-Abl–mediated murine bone marrow transformation. Together, these results reveal a mechanism of how
Bcr-Abl may overcome SOCS-1 and SOCS-3 inhibition to constitutively activate the JAK/STAT–dependent signal-
ing, and suggest that Bcr-Abl may critically requires tyrosine phosphorylation of SOCS-1 and SOCS-3 to mediate
tumorigenesis when these SOCS proteins are present in cells.
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Introduction
Cytokine-mediated activation of Janus tyrosine kinases (JAKs) leads to
phosphorylation of cytokine receptor, which assists in the recruitment
of signal transducers and activators of transcription (STAT) protein,
which is then phosphorylated, dimerized, and translocated to the
nucleus to initiate transcription of specific target genes [1]. Previous
studies have demonstrated that constitutive activation of JAK/STAT
signaling is required for efficient transformation by the Abelson
murine leukemia virus (A-MuLV), which expresses v-Abl [2]. There
is considerable evidence that dysregulated JAK/STAT signaling plays
a critical role in Bcr-Abl–induced malignant transformation [3,4].
JAKs and STAT5 were shown to be constitutively activated in Bcr-
Abl–expressing cell lines and peripheral blood cells [5–7]. Although
it was previously reported that Bcr-Abl can activate STAT5 inde-
pendent of JAK [7], activation of JAK2 was detected in blood cells
from patients with chronic myelogenous leukemia (CML) expressing
Bcr-Abl [8]. Treatment of CML cell lines with JAK2 inhibitors or a
kinase-inactive JAK2 mutant inhibited downstream effectors and
blocked Bcr-Abl–mediated tumor formation [8–10]. Moreover, high
STAT5 levels rendered CML cells resistant to imatinib and promoted
tumor progression [11]. Recently, pimozide has been identified as
STAT5 inhibitor that can control CML malignancy with imatinib
[12]. In vivo experiments using mouse models have also portrayed
STAT5 as an indispensible factor for induction and maintenance
of Bcr-Abl–positive leukemia [13]. Together, these studies suggest that
the JAK and STAT are important factors that contribute to Bcr–Abl–
induced tumorigenesis.
An important mechanism for negative regulation of the JAK/
STAT signaling pathway is mediated through members of the sup-
pressor of cytokine signaling (SOCS) family [14]. Of the eight family
members, SOCS-1 and SOCS-3 have been most extensively studied
and are the most potent inhibitors of cytokine-induced signaling.
SOCS-1 and SOCS-3 regulate JAK activity by at least two mecha-
nisms. One mechanism involves direct interaction with JAKs by their
kinase inhibitory region (KIR), which inhibits JAKs activity. The other
mechanism involves interaction of SOCS box with the Elongin BC
complex, which becomes part of an E3 ubiquitin ligase that targets
JAKs to proteasomal degradation [15–17]. When overexpressed in
cells, SOCS-1 and SOCS-3 can inhibit STAT activation induced by
multiple cytokines stimulations.
Because activation of JAK/STAT signaling is required for transfor-
mation by several oncogenes, it has been proposed that the regulatory
effects of SOCS-1 and SOCS-3 may need to be overcome to achieve
cellular transformation. Indeed, SOCS-1 locus was methylated in
different tumor types including hepatocellular carcinomas and mul-
tiple myeloma [18–20]. Several reports have found loss-of-function
mutation of SOCS-1 gene in various malignancies [21–23]. Moreover,
hypermethylation silencing of SOCS-3 facilitates cell growth in a variety
of tumors, including human lung cancer and hepatocellular carcinoma
[24–26]. SOCS-3 has been shown to function as an antisurvival agent
in breast cancer [27]. Conversely, constitutive expression of SOCS-3
protects cells from growth inhibition in T-cell lymphoma treated with
interferon α (IFN-α) [28]. Therefore, SOCS-3 is documented as an
important regulator in tumor growth.
So far, no genetic mutations of SOCS-1 and SOCS-3 genes have
been demonstrated in CML samples. The methylation status of
SOCS-1 gene in CML samples has recently been addressed by several
publications. One group demonstrated that the SOCS-1 gene was
hypermethylated in 67% and 46% of the blastic and chronic phase
CML samples, respectively, suggesting a relation between SOCS-1
gene hypermethylation and CML progression [29]. In contrast, a sec-
ond group revealed no such correlation by showing unmethylated
promoter region of SOCS-1 in all 56 CML patient samples [30].
A third group demonstrated that SOCS-1 was constitutively ex-
pressed in 49 (65%) of 75 patients with CML [31]. However, little
information is available about methylation of SOCS-3 gene in pa-
tients with CML. The principal tyrosine phosphorylation residues
of SOCS-3 have been identified [32], and the myeloproliferative
disorder–associated JAK2(V617F) mutant can bypass the negative
feedback of SOCS-3 through tyrosine phosphorylating SOCS-3
[33,34]. Together, these observations prompted us to explore the
hypothesis that the functions of SOCS-1 and SOCS-3 may be altered
in Bcr-Abl–positive cells.
In this study, we have found that Bcr-Abl signaling leads to tyrosine
phosphorylation of SOCS-1 and SOCS-3 and thereby impairs the
ability of SOCS-1 and SOCS-3 to inhibit the activation of the JAK/
STAT signaling. Interestingly, SOCS-1 is highly tyrosine phosphory-
lated in one of five Bcr-Abl–positive CML samples. Disrupting the
tyrosine phosphorylation of SOCS-1 and SOCS-3 promotes the apop-
tosis of K562 cells and blocks the tumor formation in nude mice.
Together, these results reveal a requirement for tyrosine phosphoryla-
tion of SOCS-1 and SOCS-3 in Bcr-Abl–induced tumorigenesis in
the presence of these SOCS proteins.
Materials and Methods
Antibodies
The following antibodies were used in this study: anti–phosphotyrosine
clone 4G10 (Millipore, Billerica, MA); anti-JAK1, anti–phospho-JAK1,
anti-His, anti-Bcr, and anti-Myc (Santa Cruz Biotechnology, Santa
Cruz, CA); anti-JAK2 and anti–phospho-JAK2, anti-STAT5, and
anti–phospho-STAT5 (Cell Signaling Technology, Boston, MA);
anti–X-press (Invitrogen, Carlsbad, CA); anti-Flag (Sigma, St Louis,
MO); anti–SOCS-1 polyclonal Ab (Abcam, Cambridge, MA), anti–
SOCS-1 clone 4H1 (a gift from Dr. Doug Hilton, WEHI, Victoria,
Australia). Anti–SOCS-3 antiserum was generated in the laboratory
as described previously [35]. All other antibodies were obtained as
previously described [36,37].
Site-Directed Mutagenesis and Plasmid Construction
The mutants, SOCS-1(Y65F), SOCS-1(Y81F), SOCS-1(Y155F),
SOCS-1(Y204F), SOCS-3(Y204F), SOCS-3(Y221F), and SOCS-3
(Y204, 221F), were generated by site-directed mutagenesis with the
QuickChange XL system (Stratagene, La Jolla, CA). Six SOCS fam-
ily members (SOCS 1, 2, 3, 5, 6, and 7) were subcloned into the
pcDNA3.1 (−) vector, respectively. Wild-type (WT) SOCS-1, SOCS-3,
and their mutants were subcloned into the pFLAG-CMV-5 vector and
the retroviral vectors pMIG.-IRES-GFP and MSCV p210-IRES-GFP
(a kind gift from Dr. Richard Van Etten, Tufts University, Boston, MA).
Virus Production and Generation of Stable K562 Cell Lines
Replication incompetent retroviruses were produced by transient
cotransfection of 293T cells with pMIG bicistronic retroviral vector
containing specific genes, pCL-Eco and pCL-VSV-G plasmids. K562
cell lines stably expressing specific genes were generated by infecting
the cells with retroviruses encoding GFP alone or GFP and SOCS-1,
SOCS-3, or their mutants as previously described [37].
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Cell Extracts, Immunoprecipitation, and Western Blot
Preparation of cell extracts and immunoprecipitation were per-
formed as previously described [5,37]. Briefly, cell extracts were
immunoprecipitated overnight at 4°C with indicated antibodies.
Samples were separated on SDS–polyacrylamide gel, transferred to
a nitrocellulose membrane, and probed with antibodies as indicated.
Expression of GST Fusion Proteins and In Vitro
Binding Experiment
GST fusion proteins were expressed in the bacteria BL21 (DE3)
and purified as previously described [35,38]. Pull-down experiments
were performed by incubating the beads with cell extracts treated
with either mock or λ phosphatase. Bound materials were washed
extensively and analyzed by Western blot.
Flow Cytometry and Apoptosis Assay
Cells were washed extensively in medium and cultured with etopo-
side (Sigma) for the indicated times. Then, cells were washed with
phosphate-buffered saline buffer and stained with 1 μg/ml propidium
iodode in phosphate-buffered saline. The samples were analyzed by
fluorescence-activated cell sorter (BD Bioscience, San Jose, CA).
Nude Mouse Injection
Cells (1 × 107) were injected subcutaneously into female nude
mouse (5-6 weeks old). Tumor growth was monitored and measured
in volume (length × height × width) at the indicated time points during
a 21-day period after inoculation. In addition, bioluminescent imag-
ing was performed to detect tumors from GFP-expressing K562 cells.
Mice were anesthetized using 2% isoflurane and imaged using a cooled
CCD camera. Images were quantified as photons/s using the indigo
software (Berthold Technologies, Germany). Bioluminescent imaging
was performed at day 14 after inoculation.
Primary Murine Bone Marrow Transformation Assay
Bone marrow cells were freshly harvested from 5- to 6-week-old
female Balb/c mice and then subjected to red cell lysis. Bcr-Abl–
mediated bone marrow cell transformation was performed as previ-
ously described [39,40]. Infected cells were seeded in 96-well plates
and cultured as previously described [36–38]. Ninety-six–well plates
were then examined under a microscope to determine the trans-
formed cell clones showing cytokine-independent growth, and trans-
formation efficiency was scored by counting the number of wells
containing the survivors 3 weeks after infection.
Results
SOCS-1 and SOCS-3 Are Tyrosine Phosphorylated in
Bcr-Abl–Expressing Cells
SOCS proteins constitute a class of negative regulators of JAK/STAT
signaling pathway. However, little is known about how Bcr-Abl is
able to overcome regulatory effects of SOCS proteins and impart con-
stitutive activation of JAK/STAT pathway. Therefore, we determined
whether Bcr-Abl could induce phosphorylation of SOCS proteins.
We coexpressed Bcr-Abl with Xpress and His-tagged SOCS-1, 2,
3, 5, 6, and 7 in 293T cells. As shown in Figure 1A, SOCS-1 and
SOCS-3 were clearly tyrosine phosphorylated in cells expressing
Bcr-Abl.We also observed that Bcr-Abl was coimmunoprecipitated with
SOCS-1 and SOCS-3. On the basis of these results, we focused on
SOCS-1 and SOCS-3 in this study.
Figure 1. SOCS-1 and SOCS-3 are tyrosine phosphorylated in Bcr-Abl expressing cells. (A) 293T cells were cotransfected with Bcr-Abl
and SOCS-1, SOCS-2, SOCS-3, SOCS-5, SOCS-6, or SOCS-7 using Lipofectamine. After 48 hours of culture, cells were harvested and cell
extracts were then prepared. The SOCS proteins were immunoprecipitated using the His-Tag, and immunoblot analysis was performed
using X-press antibody, p-Tyr antibody (4G10), and Abl antibody (AB-2). (B and C) 293T cells were cotransfected with Bcr-Abl and either
Flag-tagged SOCS-1 (B) or Flag-tagged SOCS-3 (C). SOCS-1 or SOCS-3 protein was then immunoprecipitated using Flag-tagged protein
IP kit (Sigma). Shown are immunoblots probed with anti–SOCS-1 antibody (4H1), anti–SOCS-3 antiserum, and p-Tyr antibody (4G10).
Neoplasia Vol. 14, No. 6, 2012 Role of Bcr-Abl–Mediated SOCS Phosphorylation Qiu et al. 549
To further confirm Bcr-Abl–dependent phosphorylation of
SOCS-1 and SOCS-3, we repeated the cotransfection experiment
using Flag-tagged SOCS-1 or SOCS-3 with Bcr-Abl. Indeed, SOCS-1
and SOCS-3 were found to be highly tyrosine phosphorylated in
Bcr-Abl–expressing cells (Figure 1, B and C).
Identification of Bcr-Abl–Dependent Phosphorylation Sites
of SOCS-1 and SOCS-3
We next sought to identify the tyrosine residues in SOCS-1 that
could be phosphorylated by Bcr-Abl. All four tyrosine residues Y65,
Y81, Y155, and Y204 were individually substituted with phenylalanine,
and phosphorylation was analyzed in 293T cells cotransfected with
Bcr-Abl and SOCS-1. The results showed that Bcr-Abl–dependent
phosphorylation of SOCS-1 occurred mainly on Y155 and Y204, to
a lesser extent, on Y81 residue (Figure 2A). Tyrosine residues at 81
and 155 are located in SH2 domain of SOCS-1, and tyrosine 204 is
within the conserved SOCS box. Again, we observed that Bcr-Abl was
brought down when SOCS-1 was immunoprecipitated (Figure 2A).
SOCS-3 is known to be tyrosine-phosphorylated on Y204 and
Y221 within the conserved SOCS box motif by several kinases [32].
In this study, we mutated these tyrosine residues to phenylalanine
either individually or in combination and analyzed phosphorylation
statuses of SOCS-3 in 293T cells. The level of phosphorylation of
SOCS-3(Y221F) mutant was greatly reduced and that of SOCS-3
(Y204F) was slightly decreased (Figure 2B). The tyrosine phosphory-
lation of a mutant with replacement of both tyrosines 204 and 221
Figure 2. Identification of Bcr-Abl–dependent phosphorylation sites of SOCS-1 and SOCS-3 and detection of SOCS-1 tyrosine phos-
phorylation in primary CML samples. (A) 293T cells were cotransfected with Bcr-Abl and either SOCS-1 or its mutants as described in
Figure 1. Immunoblot analysis of whole cell lysates was performed to examine Bcr-Abl expression. Whole cell lysates were immuno-
precipitatedwith anti–Flag-SOCS-1 antibody, and then precipitated proteins were examined for SOCS-1, Bcr-Abl, and tyrosine-phosphorylated
SOCS-1 using antibodies as indicated. (B) Experiments were performed as described in A. 293T cells cotransfected with Bcr-Abl and
Myc-tagged wild-type or mutant SOCS-3 were lysed and immunoprecipitated with anti-Myc antibody (9E10). Shown are immunoblots
probed with indicated antibodies. (C) Lysates of peripheral blood white cells from three CML patients were examined using an mAb (4H1)
directed against the N-terminal region of SOCS-1 and a rabbit polyclonal Ab directed against C-terminal SOCS box (upper panel). SOCS-1 pro-
tein levels were also examined in peripheral blood white cells from normal controls (lower panel). (D) Expression levels of SOCS-1 were
examined in five CML samples (patients 1-3 are the same as in C) after normalizing to actin loading control. (E) Lysates derived from the
five CML samples in D were immunoprecipitated with anti–SOCS-1 antibody. Precipitated proteins were probed with indicated antibodies
by Western blot analysis. (F) Lysates as described in D were used to detect total JAK2 and pJAK2 levels. Shown is an immunoblot probed
as indicated.
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with phenylalanines (SOCS-3(Y204, 221F)) was undetectable (Fig-
ure 2B). Interestingly, we also found that Bcr-Abl was brought down
when SOCS-3 was immunoprecipitated, and the amount of co-
precipitated Bcr-Abl was decreased in correlation with the reduction
of SOCS-3 phosphorylation (Figure 2B). The interaction between
Bcr-Abl and SOCS proteins was further confirmed when anti-Flag
was used to precipitate Bcr-Abl (Figure W1). Together, these results
demonstrate that Bcr-Abl signaling leads to tyrosine phosphorylation
of SOCS-1 and SOCS-3 and suggest that phosphorylation of these
SOCS proteins is associated with their interaction with Bcr-Abl.
Tyrosine Phosphorylation of SOCS-1 Occurs in CML Patients
Of the eight family members, SOCS-1 is the most potent inhibitor
of JAK/STAT signaling. Therefore, we next determined whether
SOCS-1 is expressed and tyrosine phosphorylated in patients with
Bcr-Abl–positive CML. To this end, we used two anti–SOCS-1 anti-
bodies (see Materials and Methods) to detect SOCS-1 protein levels in
these samples derived from chronic phases at diagnosis. Both anti-
bodies detected a same band at ∼37 kDa (Figure 2C). As expected,
the peripheral blood cells from normal controls exhibited an extremely
low level of SOCS-1 protein (Figure 2C ). Interestingly, after nor-
malizing to actin loading control, we observed that levels of SOCS-1
protein were varied among five CML samples (Figure 2D). These data
may support the previous idea that SOCS-1 gene is epigenetically regu-
lated in some, but not all, patients with CML [29].
Next, we examined the SOCS-1 phosphorylation status of the
cell lysates derived from the five patients with primary CML using
immunoprecipitation experiments. We found that SOCS-1 derived
from one of the CML samples was highly tyrosine phosphorylated.
In addition, SOCS-1 in two samples was tyrosine phosphorylated to
a small degree (Figure 2E ). Interestingly, robust activation of JAK2
was detected in the CML sample containing highly tyrosine phos-
phorylated SOCS-1 (Figure 2F ). The data may imply a correlation
between SOCS-1 phosphorylation and the activation of JAK2 in CML.
Moreover, JAK2 in the other three samples was also observed to be
phosphorylated (Figure 2F). The results suggested that the inhibitory
function of SOCS-1 may be altered in CML.
Bcr-Abl–Dependent Phosphorylation of SOCS-1 and
SOCS-3 Alters Their Inhibitory Effects on JAK1 Activation
and Disrupts Interaction between SOCS-1 and Elongin
BC Complex
To determine whether Bcr-Abl–dependent tyrosine phosphorylation
can alter SOCS-1 function, we investigated the effect of Bcr-Abl on
SOCS-1–dependent JAK1 degradation in a transient transfection sys-
tem using 293T cells. As expected, when SOCS-1 was cotransfected
with JAK1, a marked decrease in JAK1 protein and phospho-JAK1
(pJAK1) was observed compared with cells expressing JAK1 alone
(Figure 3A). This is consistent with previous studies demonstrating
that SOCS-1 targets JAK to the proteasome for degradation [38]. In
addition, mutant SOCS-1 carrying either Y155F or Y204F also sig-
nificantly reduced JAK1 protein levels, demonstrating that this ability
was not affected by the mutations. Importantly, when we coexpressed
Bcr-Abl with JAK1 and SOCS-1, both JAK1 protein and pJAK1 levels
were restored (Figure 3A, lane 4). The expression of Bcr-Abl had
no significant effect on the levels of JAK1 protein and pJAK1 (Fig-
ure W2A). However, JAK1 and pJAK1 levels in the context of cells
expressing SOCS-1(Y155F) or SOCS-1(Y204F) experienced a reduc-
tion with respect to those in cells expressing SOCS-1(WT) in the pres-
ence of Bcr-Abl (Figure 3A). These observations support the notion
that Bcr-Abl signaling inhibits SOCS-1–dependent degradation of
activated JAK1 through phosphorylation of SOCS-1.
Because the interaction between SOCS-1 and the Elongin BC
complex is thought to link JAK1 to degradation [38,41], we in-
vestigated whether Bcr-Abl–dependent phosphorylation of SOCS-1
had any effect on the interaction between SOCS-1 and Elongin C.
The results from in vitro binding experiments showed that the
amount of SOCS-1 that associated with Elongin C greatly decreased
in the presence of Bcr-Abl, whereas the level of bound SOCS-1
dramatically increased when cell extracts were treated with λ phos-
phatase (Figure 3B). Furthermore, we introduced SOCS-1(WT) or
SOCS-1(Y155F) into Bcr-Abl–expressing K562 cells. As expected,
mutation of Y155F increased the amount of Elongin C bound
SOCS-1 due to decreased tyrosine phosphorylation (Figure 3C). These
data suggest that Bcr-Abl–dependent phosphorylation of SOCS-1
disrupts its interaction with Elongin C, and thereby the ability of
SOCS-1 to target activated JAK1 to the proteasome is altered.
We next investigated the effects of tyrosine-phosphorylated SOCS-3
on regulating the activation of JAK1. We found that, although JAK1
protein levels were only slightly decreased by coexpressing SOCS-3,
a dramatic reduction of pJAK1 was observed in the presence of
SOCS-3 (Figure 3D). Interestingly, the results from the experiment
coexpressing Bcr-Abl with SOCS-3 and JAK1 showed a restoration
of the levels of pJAK1 compared with that in cells expressing JAK1
(Figure 3D). When cells were cotransfected with JAK1 and SOCS-3
(Y204F), SOCS-3(Y221F), or SOCS-3(Y204, 221F), a dramatic
decrease in pJAK1 was also observed although the JAK1 protein levels
were not significantly changed (Figure 3, D and E). Importantly, even
if Bcr-Abl was present, phosphorylation of JAK1 was still maintained
at low levels in cells expressing these SOCS-3 mutants (Figure 3, D
and E). Together, these results suggest that Bcr-Abl–dependent tyro-
sine phosphorylation of SOCS-1 and SOCS-3 abolishes their abilities
to inhibit the activation of JAK1.
Bcr-Abl–Dependent Phosphorylation of SOCS-1 and
SOCS-3 Impairs Their Ability to Negatively Regulate
JAK2 Activation
It has been shown that JAK2 is constitutively tyrosine phosphory-
lated in a number of Bcr-Abl–expressing cells [8]. Because SOCS
proteins negatively regulate JAK2 activity, we reasoned that the abil-
ity of SOCS proteins to regulate activated JAK2 has been impaired
in these cells. To address this possibility, SOCS1 or SOCS-3 was co-
expressed with JAK2 and either with or without Bcr-Abl in 293T
cells. When overexpressed in 293T cells, JAK2 became activated
independently of Bcr-Abl oncoprotein (FigureW2B). Our data showed
that the protein levels of JAK2 were not significantly affected by the
expression of SOCS-1, SOCS-3, or their mutants, regardless of the
presence of Bcr-Abl (Figure 4). In contrast, phosphorylation of JAK2
was dramatically inhibited by these SOCS proteins (Figure 4). Interest-
ingly, when Bcr-Abl was coexpressed with JAK2 and either SOCS-1 or
SOCS-3, a marked increase in phospho-JAK2 (pJAK2) levels was ob-
served compared with cells expressing JAK2 and SOCS-1 or SOCS-3
but without Bcr-Abl (Figure 4, A and B, lanes 4). However, this effect
was abrogated when tyrosine phosphorylation sites–mutated SOCS-1
or SOCS-3 was expressed in cells (Figure 4). Strikingly, pJAK2 levels
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in cells expressing Bcr-Abl and SOCS-1(Y204F), SOCS-3(Y221F), or
SOCS-3(Y204, 221F) were reduced to levels similar to those observed
in the absence of Bcr-Abl (Figure 4, A and B, lanes 8, and C , lane 6 ).
Together, these data suggest that, after being tyrosine phosphorylated
in Bcr-Abl–expressing cells, the ability of SOCS-1 and SOCS-3 to neg-
atively regulate JAK2 activation is impaired.
Activation of JAK/STAT Signaling in Bcr-Abl Positive K562
Leukemic Cells Is Attenuated When Tyrosine Phosphorylation
of SOCS-1 or SOCS-3 Is Disrupted
Activated JAK/STAT signaling is thought to play a critical role in
Bcr-Abl–mediated tumorigenicity [3,4]. Indeed, we observed that
JAK2 and STAT5 were phosphorylated in K562 leukemic cells
Figure 3. Bcr-Abl–dependent phosphorylation of SOCS-1 and SOCS-3 alters their inhibitory effects on JAK1 activation and disrupts
interaction between SOCS-1 and Elongin BC complex. (A) JAK1 was cotransfected with empty vector, wild-type, or mutant SOCS-1 with
or without Bcr-Abl in 293T cells as described in Figure 1. The levels of protein expression and tyrosine-phosphorylated JAK1(pY-JAK1)
were examined by Western blot analysis. (B) The interaction between SOCS-1 and Elongin BC was examined by in vitro binding assays.
Glutathione beads coupled to either GST alone or GST-Elongin C were incubated with extracts derived from 293T cells overexpressing
Bcr-Abl and SOCS-1 and either treated with λ phosphatase or mock treated. SOCS-1 bound was detected by Western blot analysis.
(C) GST pull-down experiments with glutathione beads were performed as described in B. Either GST beads or GST–Elongin C beads
were incubated with extracts from K562 cells ectopically expressing SOCS-1(WT) or SOCS-1(Y155F). Cell lysates were either mock or
λ phosphatase treated. The immunoblots were probed as indicated. (D and E) 293T cells were cotransfected with JAK1 and either empty
vector, SOCS-3(WT), SOCS-3(Y204F), and SOCS-3(Y221F) (D) or SOCS-3(Y204, 221F) (E) with or without Bcr-Abl. Protein levels and
pY-JAK1 were examined by Western blot analysis using indicated antibodies.
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(Figure 5). To explore whether tyrosine phosphorylation status of
SOCS-1 and SOCS-3 determines their ability to negatively regulate
JAK/STAT activation in leukemic cells, we generated K562 cell lines
stably expressing GFP alone, SOCS-1(WT), SOCS-3(WT), or their
mutants using bicistronic retroviruses (Figures W3 and W4). Impor-
tantly, our experiments demonstrated that tyrosine phosphorylation
of SOCS-1(WT) or SOCS-3(WT) proteins is Bcr-Abl kinase depen-
dent in K562 cells (Figure 5A). The cell lines infected with the retro-
viruses encoding SOCS or their mutants expressed comparable levels
of these proteins (Figure 5, B and C ). Interestingly, we observed that,
in K562 cells expressing SOCS-1(WT) or SOCS-3(WT), endo-
genous JAK2 and STAT5 were constitutively activated and SOCS-1
and SOCS-3 were tyrosine phosphorylated (Figure 5, B and C). How-
ever, the levels of pJAK2 and pSTAT5 were significantly decreased in
cells expressing SOCS-1(Y155F) or SOCS-1(Y204F) compared with
the control cells. Surprisingly, SOCS-1(Y204F) displayed more pro-
found effects on the activation of JAK2 and STAT5 than SOCS-1
(Y155F) did, although SOCS-1(Y204F) was phosphorylated to a
greater degree than SOCS-1(Y155F) (Figure 5B). The data suggest
that Bcr-Abl–dependent tyrosine phosphorylation of SOCS-1 at Y204
within SOCS box is critical for altering SOCS-1 function.
Similarly, the levels of pJAK2 and pSTAT5 were dramatically re-
duced in K562 cells expressing SOCS-3(Y221F) or SOCS-3(Y204,
221F) without affecting the total protein levels of JAK2 and STAT5
(Figure 5C ). K562 cells expressing SOCS-3(Y204F) exhibited a
slightly decreased level of pJAK2 but unchanged level of pSTAT5
compared with control cells. Together, these experiments demon-
strated that Bcr-Abl–dependent tyrosine phosphorylation of SOCS-1
and SOCS-3 coincided with the activation of JAK2 and STAT5 in
K562 leukemic cells.
Disrupting the Tyrosine Phosphorylation of SOCS-1 or
SOCS-3 Sensitizes K562 Cells to Undergo Apoptosis
Because activation of JAK2 and STAT5 was inhibited by disrupting
the tyrosine phosphorylation of SOCS-1 or SOCS-3 and given that ac-
tivation of JAK2/STAT5 signaling contributes to increased cell survival,
we hypothesized that decreasing the levels of tyrosine-phosphorylated
SOCS-1 or SOCS-3 might sensitize K562 cells to undergo apoptosis in
response to drug treatment. As shown in Figure 6A, 77.5% of K562
cells expressing GFP control and 64.4% of cells expressing SOCS-1
(WT) remained viable after treatment with etoposide for 48 hours
under our culture condition. However, only 33.8% of K562 cells ex-
pressing SOCS-1(Y155F) and 21.7% of cells expressing SOCS-1
(Y204F) were viable under the same culture conditions (Figure 6A).
As expected, 70.4% of cells expressing SOCS-3(WT) remained viable
after treatment with etoposide for 48 hours, which was comparable
to that of control cells (Figure 6B). Strikingly, only 28.7% of K562
cells expressing SOCS-3(Y221F) were viable, whereas 63.4% of K562
cells expressing SOCS-3(Y204F) were viable under the same condi-
tions (Figure 6B). Together, these data indicate that disrupting the
tyrosine phosphorylation of SOCS-1 or SOCS-3 sensitizes K562 cells
to undergo apoptosis.
Previous studies have suggested that inefficient apoptotic signaling in
Bcr-Abl transformed cells may be attributed to the STAT5-dependent
expression of antiapoptotic Bcl-XL protein [42]. Therefore, we rea-
soned that increased apoptosis of K562 cells expressing SOCS mu-
tants presented above was likely due to impaired expression of Bcl-XL.
To test this possibility, we examined the levels of Bcl-XL and Bcl-2 in
K562 cell lines stably expressing GFP control, SOCS-1(WT), SOCS-3
Figure 4. Bcr-Abl–dependent phosphorylation of SOCS-1 and
SOCS-3 impairs their ability to negatively regulate JAK2 activation.
(A) 293T cells were cotransfected with JAK2 and empty vector,
wild-type, or mutant SOCS-1 in the presence or absence of Bcr-Abl
as described in Figure 1. Cell lysates were examined for levels of
JAK2, phosphor-JAK2, Bcr-Abl, and SOCS-1 using immunoblot
analysis assay. (B and C) Experiments were carried out as described
in A. JAK2 was coexpressed with either empty vector, SOCS-3(WT),
SOCS-3(Y204F), and SOCS-3(Y221F) (B) or SOCS-3(Y204, 221F)
(C) in the presence or absence of Bcr-Abl. Shown are immunoblots
probed as indicated.
Neoplasia Vol. 14, No. 6, 2012 Role of Bcr-Abl–Mediated SOCS Phosphorylation Qiu et al. 553
(WT), or their mutants. Indeed, we observed that the level of Bcl-XL
significantly decreased in K562 cells expressing SOCS-1(Y155F),
SOCS-1(Y204F), SOCS-3(Y221F), or SOCS-3(Y204, 221F) com-
pared with those in cells expressing wild-type SOCS proteins or GFP
alone (Figure 6C ). In contrast, no significant changes in protein
expression of Bcl-2 were seen in cells expressing these SOCS mutants
(Figure 6D).
Selective Mutation of Tyrosine Phosphorylation Sites of
SOCS-1 or SOCS-3 Completely Blocks Tumor Formation
Caused by K562 Cells in Mouse Model
An important extension of our hypothesis was to establish whether
tyrosine phosphorylation of SOCS-1 or SOCS-3 is required for Bcr-
Abl–induced tumorigensis. To this end, we injected nude mice
subcutaneously with K562 cells stably expressing SOCS-1(WT),
SOCS-1(Y155F), SOCS-1(Y204F),, or GFP alone. Tumor growth
was examined every week after inoculation. Tumors were detected
about 7 days after inoculation in most of the nude mice challenged
with K562 cells expressing SOCS-1(WT), SOCS-1(Y155F), or GFP
control. Importantly, tumors formed by cells expressing GFP or
SOCS-1(WT) grew clearly faster than tumors formed by cells express-
ing SOCS-1(Y155F). However, during the 3 weeks after inocula-
tion, tumors were invisible in all mice receiving K562 cells expressing
SOCS-1(Y204F), suggesting that phosphorylation of tyrosine 204
residue within SOCS-1 box is required for tumor formation caused
by K562 cells (Figures 7, A and C , and W5A).
To test the involvement of SOCS-3 phosphorylation in tumor
formation, nude mice were inoculated subcutaneously with K562 cells
expressing SOCS-3(WT), its mutants, or GFP control. We found that
tumor growth was inhibited by Y204F mutation and was completely
blocked by Y221F mutation or Y204/221F double mutation of
SOCS-3 (Figures 7, B and C , and W5B). These experiments were
repeated at least three times to ensure specificity of the results and
consistency of data.
To further examine the involvement of tyrosine phosphorylation of
SOCS-1 and SOCS-3 in Bcr-Abl–mediated cellular transformation,
we generated bicistronic retroviruses encoding Bcr-Abl and GFP,
SOCS-1(WT), SOCS-3(WT), SOCS-1(Y204F), or SOCS-3(Y204,
221F) because these mutants had profound effect on the tumor
growth (Figure W6). Primary murine bone marrow cells were infected
with equal titer of the viruses and the capacity of these viruses to
Figure 5. Activation of JAK/STAT signaling in K562 cells is attenuated when tyrosine phosphorylation of SOCS-1 or SOCS-3 is disrupted.
(A) Shown are immunoblots of K562 cells ectopically expressing SOCS-1(WT) or SOCS-3(WT). Cells were treated with or without imatinib
and probed with indicated antibodies. (B) K562 cells ectopically expressing Myc-tagged wild-type or mutant SOCS-1 were lysed and ex-
amined for endogenous Bcr-Abl, JAK2, phospho-JAK2 (pJAK2), STAT5, and phospho-STAT5 (pSTAT5). The same lysates were immuno-
precipitated with anti-Myc antibody (9E10), and precipitated proteins were then examined for SOCS-1 total protein and pY-SOCS-1 levels.
(C) Immunoblot of lysates from K562 cells ectopically expressing Flag-tagged wild-type or mutant SOCS-3 was probed as indicated.
The lysates were also immunoprecipitated with anti-Flag antibody and then examined for SOCS-3 and pY-SOCS-3 levels by Western
blot analysis.
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transform bone marrow cells was measured by counting the number of
Bcr-Abl–transformed cell clones. As shown in Figure 7D, cells infected
with viruses carrying Bcr-Abl-IRES-GFP, Bcr-Abl-IRES-SOCS-1
(WT), or Bcr-Abl-IRES-SOCS-3(WT) displayed Bcr-Abl transforma-
tion with average results of 16.00, 13.67, and 14.67 wells, showing
growth of cell clones per 96-well plate, respectively. Importantly,
under the same conditions, expression of SOCS-1(Y204F) or SOCS-3
(Y204, 221F) significantly decreased Bcr-Abl transformation efficiency
to 4.33 and 4.00 wells per 96-well plate, respectively (Figure 7D). Taken
together, these experiments provide strong evidence that Bcr-Abl–
mediated tumorigenesis critically requires robust tyrosine phosphoryla-
tion of SOCS-1 and SOCS-3 when these SOCS proteins are present
in the cells.
Discussion
SOCS proteins are identified as negative regulators of JAK/STAT
signaling and play important roles in many immunologic and patho-
logic processes [43,44]. A previous study has shown that v-Abl can
bypass SOCS-1 inhibition and reduce its ability to inhibit JAK1 activa-
tion through phosphorylation of SOCS-1 [38]. It has been shown that
SOCS-3 is tyrosine phosphorylated in cells stimulated with cytokines
such as IL-2, IL-3, and growth factors [32]. Interestingly, the myelo-
proliferative disorder-associated JAK2(V617F) mutant can escape
negative regulation of SOCS-3 through tyrosine phosphorylation
of this SOCS protein [33]. Although JAK/STAT signaling plays an
important role in Bcr-Abl–induced tumorigenicity, the precise mecha-
nism by which Bcr-Abl overcomes regulatory effects of SOCS proteins
Figure 6. Disrupting the tyrosine phosphorylation of SOCS-1 or SOCS-3 promotes K562 cells to undergo apoptosis. (A) K562 cells
ectopically expressing empty vector, SOCS-1, or its mutants were treated with 50 μM etoposide at indicated times. Apoptosis and
cell survival were analyzed by the propidium iodide staining and measured by flow cytometry. Plotted are the results from three in-
dependent experiments. Error bars, SD. (B) K562 cells expressing empty vector, SOCS-3(WT), SOCS-3(Y204F), or SOCS-3(Y221F)
were exposed to etoposide and cell survival was examined as described in A. Three independent experiments were performed. Error
bars, SD. (C and D) K562 cell lines described above were analyzed by Western blot analysis to detect Bcl-XL protein levels (C) and Bcl-2
protein levels (D).
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Figure 7. Decreasing tyrosine phosphorylation levels of SOCS-1 or SOCS-3 efficaciously inhibits tumor formation in mouse model and
transformation of primary murine bone marrow cells. (A) Nude mice were subcutaneously injected with K562 cells stably expressing
empty vector, SOCS-1(WT), SOCS-1(Y155F), or SOCS-1(Y204F). The mice were monitored for visible signs of tumor growth, and tumor
volumes were measured at indicated time points. The groups labeled by letter a are different from the ones labeled by letter b at the
significant level of P ≤ .01, and the groups of a and b are different from the ones labeled by letter c at the significant level of P ≤ .001.
Plotted are the results from three independent experiments. Error bars, SD; n = 16. (B) Nude mice were inoculated with K562 cells
stably expressing empty vector, SOCS-3(WT), SOCS-3(Y204F), SOCS-3(Y221F), or SOCS-3(Y204, 221F). Tumor growth was analyzed as
described in A. Letters a, b, and c indicate the mean values that are different at the significant level of P ≤ .001. Error bars, SD; n = 20.
(C) Nude mice were subcutaneously injected with K562 cells as described in A and B. Over a 14-day period after inoculation, tumors
formed by K562 cells stably expressing empty vector (GFP), wild-type, or mutant SOCS-1 (upper panel) and wild-type or mutant SOCS-3
(lower panel) were measured by bioluminescent imaging. Shown are representative images from several experiments with similar results.
(D) Bonemarrow cells from Balb/c mice were infected with retroviruses expressing Bcr-Abl and GFP, SOCS-1(WT), SOCS-1(Y204F), SOCS-3
(WT), or SOCS-3(Y204, 221F) and plated on 96-well plates. Transformation efficiency was scored as described in Materials and Methods.
Plotted are the results from three independent experiments. Error bars, SEM; n = 3. *P < .01.
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and imparts constitutive activation of JAK/STAT signaling is still un-
known. Here, our experiments provide the first evidence that SOCS-1
and SOCS-3 are both tyrosine phosphorylated in a Bcr-Abl–dependent
manner. We have further identified the Bcr-Abl–dependent tyrosine
phosphorylation sites of SOCS-1 and SOCS-3. These observations
imply that Bcr-Abl may alter function of SOCS-1 and SOCS-3 through
robust tyrosine phosphorylation of these SOCS proteins to constitu-
tively activate JAK/STAT signaling. However, although our results
indicate that Bcr-Abl is associated with SOCS-1 and SOCS-3 in cells,
it is still unclear whether the binding between Bcr-Abl and SOCS is
direct and whether Bcr-Abl directly phosphorylates SOCS proteins.
Conversely, it is also unclear whether this phosphorylation is impor-
tant in physiological (non-CML) setting. These issues remain to be
further addressed.
Our data show that Bcr-Abl–dependent phosphorylation of SOCS-1
and SOCS-3 diminishes their inhibitory effects on JAK1 and JAK2
activation. Importantly, the results reveal that Bcr-Abl–dependent tyro-
sine phosphorylation of SOCS proteins impairs their activity to nega-
tively regulate STAT5 activation in K562 leukemic cells. In addition,
we demonstrate that disrupting the tyrosine phosphorylation of SOCS-1
or SOCS-3 sensitizes K562 cells to undergo apoptosis. Consistent with
this altered apoptosis profile, a decreased level of Bcl-XL was detected
in K562 cells expressing the phosphorylation site–mutated SOCS pro-
teins. Because expression of Bcl-XL is transcriptionally activated by
STAT5 [42], it is most likely that ectopically expressed SOCS mutants
inactivate STAT5 and thereby suppress STAT5-dependent expression
of Bcl-XL, which may contribute to the enhanced apoptosis of the
cells. Interestingly, we further found that selective targeting of tyrosine
phosphorylation sites of SOCS-1 or SOCS-3 completely blocks tumor
formation caused by K562 cells in nude mouse model and significantly
inhibits Bcr-Abl–mediated murine bonemarrow transformation. These
experiments provide strong evidence that Bcr-Abl–mediated tumori-
genesis critically requires inability of SOCS-1 and SOCS-3 through
robust tyrosine phosphorylation of these SOCS proteins when they are
present in the cells.
It was interesting to determine whether tyrosine phosphorylation of
SOCS-1 and SOCS-3 also occurs in other Abl-transformed cell lines
besides K562 cell. To test this possibility, we examined the SOCS-1
and SOCS-3 phosphorylation status in a v-Abl–transformed cell line
described previously [37]. Interestingly, we detected significant amount
of tyrosine phosphorylated SOCS-3 but very low level of SOCS-1 tyro-
sine phosphorylation in the v-Abl–transformed cells ectopically express-
ing these SOCS proteins (Figure W7). These data are consistent with
a previous study suggesting that v-Abl signaling leads to SOCS-1 phos-
phorylation mainly on nontyrosine residues [38]. In addition, we found
previously that expression of Pim kinases downstream of v-Abl sig-
naling resulted in an increased amount of phosphorylated SOCS-1
and thereby promoted v-Abl–mediated cellular transformation [37].
Based on these data, it is likely that Pim kinases are involved in
v-Abl–mediated SOCS-1 phosphorylation [37,38]. Together, these
experiments demonstrated that Abl oncogenes may alter SOCS func-
tion through the phosphorylation of these SOCS proteins on tyrosine
or nontyrosine residues.
Both SOCS-1 and SOCS-3 contain a highly conserved C-terminal
region termed SOCS box. The SOCS boxes of SOCS-1 and SOCS-3
have been thought to participate in the formation of an E3 ubiquitin
ligase complex that is assumed to degrade the activated signaling com-
plex [45]. Interestingly, although Bcr-Abl–dependent tyrosine phos-
phorylation of SOCS-1 occurs on Tyr 81, Tyr 155, and Tyr 204
residues, Y204F mutation seems to have the strongest impact on
activation of JAK2 and STAT5. Our results indicate that Tyr 204
within SOCS-1 box and Tyr 221 within SOCS-3 box are key residues
for altering SOCS function through phosphorylation. These data sug-
gest that SOCS boxes of these SOCS proteins are critical for SOCS
activity to negatively regulate JAK and STAT5 activation downstream
of Bcr-Abl signaling. Previous studies revealed that v-Abl signaling
could lead to phosphorylation of SOCS-1 on nontyrosine residues
[38]. The present report is the first one to assess the tyrosine phos-
phorylation status of SOCS-1 and SOCS-3 in Bcr-Abl–expressing
cells. The question of whether Bcr-Abl signaling, like v-Abl, can lead
to SOCS phosphorylation on nontyrosine residues remains to be
further determined.
Although methylation of SOCS-1 gene has been observed in patients
with CML [29], there is increasing evidence that SOCS-1 is constitu-
tively expressed in CML samples [31]. More recently, SOCS-1 expres-
sion was further confirmed in more than 50% of patients with CML
[46]. The constitutive expression of SOCS-3 was also previously found
in most CML cell lines that are resistant to treatment with IFN-α [47].
Furthermore, most of the blast cells from patients in CML blast crisis
showed constitutive expression of SOCS-3 [47]. SOCS-1 and SOCS-3
are known potent inhibitors of JAK/STAT signaling. However, the
mechanism by which Bcr-Abl bypasses SOCS regulation to constitu-
tively activate JAK/STAT pathway in CML cells has not been explored.
In this study, tyrosine-phosphorylated SOCS-1 was detected in three
of five primary CML samples, which express Bcr-Abl. We understand
that our CML sample size is limited, and our sample set did not enable
us to dissect protein expression and phosphorylation of many signal
transduction molecules at various levels to identify sites of potential
pathway activation after altering the SOCS function in CML cells.
Another large-scale study could increase the statistical power of our
results obtained from CML samples. Also, we did not investigate the
SOCS-3 expression in CML patients in this study, which remains an
ongoing task.
In summary, we demonstrate that Bcr-Abl–dependent tyrosine
phosphorylation of SOCS-1 and SOCS-3 alters inhibitory function
of these SOCS proteins. On the basis of these findings, our model sug-
gests that SOCS needs to be bypassed for transformation to occur and
may reveal a mechanism by which Abl oncogenes overcome SOCS-1
and SOCS-3 inhibition. Thus, SOCS may be therapeutically useful for
treatment of Abl-induced malignancies known to involve constitutive
activation of JAK/STAT signaling.
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Figure W1. The interaction between Bcr-Abl and SOCS proteins. 293T cells were cotransfected with Flag-tagged Bcr-Abl and either
wild-type or mutant SOCS-1 (A), wild-type or mutant SOCS-3 (B). Bcr-Abl protein was then immunoprecipitated with anti-Flag anti-
body (Sigma). Precipitated proteins were examined for SOCS proteins by Western blot analysis. Shown are immunoblots probed with
indicated antibodies.
Figure W2. When overexpressed in 293T cells, JAK1 and JAK2 become activated independently of Bcr-Abl oncoprotein. Bcr-Abl was
coexpressed with either JAK1 (A) or JAK2 (B) in 293T cells. Cell lysates were examined for JAK1 and pJAK1 (A) and JAK2 and pJAK2
(B) as indicated by Western blot analysis.
Figure W3. Generation of K562 cell lines stably expressing wild-type or mutant SOCS-1. Bicistronic retroviruses encoding GFP alone or
GFP and SOCS-1(WT) or its mutants were produced in 293T cells. Cell culture supernatants containing retroviruses were collected and
filtered through a 0.22-μm MCE membrane (Millipore). K562 cells were infected with these retroviruses by spin infection at 2000 rpm
at 32°C for 120 minutes. After additional culture for 48 hours, GFP-positive K562 cells were sorted by flow cytometry and cultured in
RPMI 1640 containing 10% fetal bovine serum. Shown are micrographs obtained from fluorescent microscope (Axiovert 200M; Zeiss,
Oberkochen, Germany).
Figure W4. K562 cell lines stably expressing wild-type or mutant SOCS-3 were generated in this study. Experiments were performed as
described in Figure W2. Bicistronic retroviruses encoding GFP alone or GFP and SOCS-3(WT) or its mutants were generated in 293T cells.
K562 cells were then infected with these retroviruses and GFP-positive K562 cells stably expressing GFP alone, GFP and SOCS-3(WT), or
its mutants were sorted by flow cytometry. Shown are micrographs obtained from fluorescent microscope (Axiovert 200M; Zeiss).
Figure W5. Disrupting Bcr-Abl–mediated tyrosine phosphorylation of SOCS-1 or SOCS-3 blocks tumor formation caused by K562 cells in
nude mouse model. Nude mice inoculated with K562 cells expressing GFP alone, wild-type, or mutant SOCS-1 (A) and wild-type or
mutant SOCS-3 (B) were killed 1 day after the last measurement of tumor growth and tumors were excised from nude mice. Shown
are representative images from at least three independent experiments with similar results.
Figure W6. Shown are bicistronic retroviral vectors used in this study. (A) Bicistronic retroviral vectors encoding Bcr-Abl and GFP, SOCS-1
(WT), SOCS-1(Y204F), SOCS-3(WT), or SOCS-3(Y204, 221F) were generated. (B and C) The expression of these bicistronic retroviral vectors
encoding Bcr-Abl and GFP, wild-type, or mutant SOCS-1 (B) and wild-type or mutant SOCS-3 (C) were examined in 293T cells. Shown are
representative Western blots probed with indicated antibodies.
Figure W7. Tyrosine phosphorylation of SOCS-1 and SOCS-3 in a v-Abl transformed cell line ectopically expressing these SOCS proteins.
v-Abl transformed cells ectopically expressing empty vector, SOCS-1 or its mutant, and SOCS-3 or its mutant were lysed and examined
for SOCS proteins and their tyrosine phosphorylated forms with indicated antibodies. Shown are representative immunoblots.
